Cargando…

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC

INTRODUCTION: Whereas tumor biopsy is the reference standard for genomic profiling of advanced NSCLC, there are now multiple assays approved by the Food and Drug Administration for liquid biopsy testing of circulating tumor DNA. Here, we study the incremental value that liquid biopsy comprehensive g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwartzberg, Lee S., Li, Gerald, Tolba, Khaled, Bourla, Ariel B., Schulze, Katja, Gadgil, Rujuta, Fine, Alexander, Lofgren, Katherine T., Graf, Ryon P., Oxnard, Geoffrey R., Daniel, Davey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460153/ https://www.ncbi.nlm.nih.gov/pubmed/36089920 http://dx.doi.org/10.1016/j.jtocrr.2022.100386

Ejemplares similares

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
por: Quintanilha, Julia C F, et al.
Publicado: (2023)

Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens
por: Hiemenz, Matthew C, et al.
Publicado: (2022)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC
por: Aerts, Hugo J. W. L., et al.
Publicado: (2016)

Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2022)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC
por: Aerts, Hugo J. W. L., et al.
Publicado: (2017)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
por: Quintanilha, Julia C.F., et al.
Publicado: (2023)

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC
por: Ma, Xinran, et al.
Publicado: (2021)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
por: Kim, So Yeon, et al.
Publicado: (2020)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
por: Santos, Edgardo S., et al.
Publicado: (2018)

Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations
por: Chatziandreou, Ilenia, et al.
Publicado: (2015)

Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform
por: Bourla, Ariel B., et al.
Publicado: (2021)

Quantifying the Selective, Stochastic, and Complementary Drivers of Institutional Evolution in Online Communities
por: Zhong, Qiankun, et al.
Publicado: (2022)

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies
por: Zurita, Amado J., et al.
Publicado: (2022)

Genomic landscape of 891 RET fusions detected across diverse solid tumor types
por: Parimi, Vamsi, et al.
Publicado: (2023)

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
por: Yoh, Kiyotaka, et al.
Publicado: (2021)

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC
por: Yang, Haitao, et al.
Publicado: (2017)

Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC
por: Desmeules, Patrice, et al.
Publicado: (2023)

Complementary and integrative interventions for PTSD
por: Niles, Barbara, et al.
Publicado: (2023)

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Ex vivo Comprehensive Multiphase NMR of whole organisms: A complementary tool to in vivo NMR
por: Ghosh Biswas, Rajshree, et al.
Publicado: (2020)

Is quality of life after mastectomy comparable to that after breast conservation surgery? A 5-year follow up study from Mumbai, India
por: Deepa, K. V., et al.
Publicado: (2019)

Comprehensive Characterization of Cancer Driver Genes and Mutations
por: Bailey, Matthew H., et al.
Publicado: (2018)

Drivers’ Comprehensive Emotion Recognition Based on HAM
por: Zhou, Dongmei, et al.
Publicado: (2023)

Complementary and Alternative Medicine Use at a Comprehensive Cancer Center
por: Luo, Qianlai, et al.
Publicado: (2016)

A Comprehensive Review of Tourette Syndrome and Complementary Alternative Medicine
por: Kumar, Ashutosh, et al.
Publicado: (2018)

Art therapy as a comprehensive complementary treatment for Parkinson’s disease
por: Ettinger, Tom, et al.
Publicado: (2023)

Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications
por: Smida, Tanner, et al.
Publicado: (2020)

Sense of Smell as the Central Driver of Pavlovian Appetite Behavior in Mammals
por: Fine, Leon G., et al.
Publicado: (2019)

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
por: Kim, Dong-Wan, et al.
Publicado: (2022)

Effects of Gene Duplication, Positive Selection, and Shifts in Gene Expression on the Evolution of the Venom Gland Transcriptome in Widow Spiders
por: Haney, Robert A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jj9js5rft40vr3jpva86u5utu2